-
公开(公告)号:US20120039882A1
公开(公告)日:2012-02-16
申请号:US13279086
申请日:2011-10-21
IPC分类号: A61K39/395 , A61P9/00 , A61K31/713 , A61K31/7088 , A61K31/7105
CPC分类号: C07K16/22 , A61K2039/505
摘要: The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided.
摘要翻译: 本发明涉及治疗血管和心脏功能受损的方法和试剂。 还提供了用于治疗与血管功能障碍和心脏功能障碍相关的各种生理和病理特征的方法和试剂。
-
2.
公开(公告)号:US08088381B2
公开(公告)日:2012-01-03
申请号:US11418624
申请日:2006-05-05
IPC分类号: A61K39/395 , G01N33/49
CPC分类号: C07K16/22 , A61K2039/505
摘要: The present invention relates to methods for treating impaired cardiac function. Methods for treating various physiological and pathological features associated with cardiac dysfunction by administering an agent that inhibits the expression or activity of connective tissue growth factor (CTGF) are provided.
摘要翻译: 本发明涉及治疗心脏功能受损的方法。 提供了通过施用抑制结缔组织生长因子(CTGF)的表达或活性的药物来治疗与心脏功能障碍相关的各种生理和病理特征的方法。
-
公开(公告)号:US20110263644A1
公开(公告)日:2011-10-27
申请号:US13180262
申请日:2011-07-11
IPC分类号: A61K31/472 , A61P9/00 , A61K31/4725
CPC分类号: A61K45/06 , A61K31/121 , A61K31/194 , A61K38/49 , A61K2300/00
摘要: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.
摘要翻译: 本发明涉及可用于治疗中风的方法和药剂,包括缺血性卒中和出血性中风。 特别地,提供了用于治疗受试者中风的方法和药剂,其中所述药物在诊断为中风之前作为缺血性中风或出血性中风进行施用。
-
公开(公告)号:US09775902B2
公开(公告)日:2017-10-03
申请号:US13180262
申请日:2011-07-11
IPC分类号: A61K31/121 , A61K31/194 , A61K45/06 , A61K38/49
CPC分类号: A61K45/06 , A61K31/121 , A61K31/194 , A61K38/49 , A61K2300/00
摘要: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.
-
-
-